- Home
- AX vs RYTM Comparison
AX vs RYTM Comparison
Compare AX & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AX
- RYTM
- Stock Information
- Founded
- AX 1999
- RYTM 2008
- Country
- AX United States
- RYTM United States
- Employees
- AX N/A
- RYTM N/A
- Industry
- AX Savings Institutions
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- AX Finance
- RYTM Health Care
- Exchange
- AX Nasdaq
- RYTM Nasdaq
- Market Cap
- AX 4.1B
- RYTM 4.3B
- IPO Year
- AX 2005
- RYTM 2017
- Fundamental
- Price
- AX $78.27
- RYTM $65.25
- Analyst Decision
- AX Strong Buy
- RYTM Strong Buy
- Analyst Count
- AX 6
- RYTM 12
- Target Price
- AX $84.00
- RYTM $77.50
- AVG Volume (30 Days)
- AX 352.3K
- RYTM 585.3K
- Earning Date
- AX 07-29-2025
- RYTM 08-05-2025
- Dividend Yield
- AX N/A
- RYTM N/A
- EPS Growth
- AX 0.28
- RYTM N/A
- EPS
- AX 7.33
- RYTM N/A
- Revenue
- AX $1,181,567,000.00
- RYTM $136,863,000.00
- Revenue This Year
- AX $21.51
- RYTM $37.56
- Revenue Next Year
- AX $4.51
- RYTM $74.99
- P/E Ratio
- AX $10.68
- RYTM N/A
- Revenue Growth
- AX 17.72
- RYTM 48.88
- 52 Week Low
- AX $54.46
- RYTM $40.46
- 52 Week High
- AX $88.46
- RYTM $69.89
- Technical
- Relative Strength Index (RSI)
- AX 65.28
- RYTM 53.08
- Support Level
- AX $74.26
- RYTM $60.80
- Resistance Level
- AX $77.35
- RYTM $64.00
- Average True Range (ATR)
- AX 1.53
- RYTM 1.96
- MACD
- AX 0.33
- RYTM -0.13
- Stochastic Oscillator
- AX 82.72
- RYTM 44.48
About AX Axos Financial Inc.
Axos Financial Inc is a bank holding company that operates through its bank subsidiary, BofI Federal Bank, a nationwide bank that provides financing for single and multifamily residential properties, small to medium-size businesses in certain sectors, and selected specialty finance receivables. Its operating segments are banking business segment and securities business segment . The bank distributed its products through a wide range of retail distribution channels, including only banking brands, affinity groups, and sales teams, among others. The majority of the bank's mortgage exposure is titled toward the state of California, particularly its southern region. Net interest income is a majority of the bank's revenue.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.